［1］LIN YL，WU XQ，LIN TQ.Trend analysis and prediction of lung cancer death and life loss in Xiamen［J］.Chinese Journal of Lung Cancer，2016，19(2)：77-81.［林艺兰，伍啸青，林田泉.厦门市居民肺癌死亡与减寿趋势分析及预测［J］.中国肺癌杂志，2016，19(2)：77-81.］
[2]Kim ES，Kim YT，Kang CH，et al.Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD［J］.International Journal of Chronic Obstructive Pulmonary Disease，2016，11(1)：1317-1326.
[3]Rosell R，Dafni U，Felip E，et al.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)：An international，multicentre，single-arm，phase 2 trial［J］.Lancet Respir Med，2017，5(5)：435-444.
[4]MA YJ，GAO T，DANG Y，et al.Clinical efficacy of bronchoscopic intervention combined with external radiation therapy for central lung cancer［J］.Journal of Clinical Lung，2017，22(1)：174-175.［马玉娟，高亭，党焱，等.经支气管镜介入联合体外放射治疗中央型肺癌的临床疗效［J］.临床肺科杂志，2017，22(1)：174-175.］
[5]Miller DA，Krasna MJ.Local therapy indications in the management of patients with oligometastatic non-small cell lung cancer［J］.Surgical Oncology Clinics of North America，2016，25(3)：611-620.
[6]Paccagnella A，Oniga F，Bearz A，et al.Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer：Results of a phase II-III study［J］.Journal of Clinical Oncology，2016，24(4)：681-687.
[7]Yalin BP，
�瘙塁
ahin B.Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey［J］.Turkish Journal of Medical Sciences，2016，46(1)：152-158.
[8]Uesaka K，Boku N，Fukutomi A，et al.Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer：A phase 3，open-label，randomised，non-inferiority trial (JASPAC 01)［J］.Lancet，2016，388(10041)：248-257.
[9]Sara B，Simona OA，Paola C，et al.Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation：A large case series study with a long-term follow-up［J］.Breast Cancer Research & Treatment，2016，157(2)：363-371.
[10]Tian J，Xu YY，Li L，et al.MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2［J］.Am J Transl Res，2017，9(3)：1127-1138.
[11]Niedersüss-Beke D，Puntus T，Kunit T，et al.Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer［J］.Oncology，2017，93(1)：36-42.
[12]Borad MJ，Reddy SG，Bahary N，et al.Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer［J］.Journal of Clinical Oncology，2016，33(13)：1475-1481.
[13]Hiraki S，Kanesada K，Harada T，et al.A case of locally advanced gallbladder cancer that developed early multiple liver metastasis after curative resection，and achieved long-term partial remission using S-1 and gemcitabine［J］.Gan To Kagaku Ryoho，2016，43(12)：2086-2088.
[14]Erratum：The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancer［J］.Acta Pharmacologica Sinica，2017，38(3)：443-443.
[15]Liu Y，Gong W，Yang ZY，et al.Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer［J］.Apoptosis：An International Journal on Programmed Cell Death，2017，22(4)：544-557.
[16]Burgess J，Bolderson E，Gray S，et al.The overexpression and cleavage of SASH1 by caspase-3 stimulates cell death in lung cancer cells［J］.Journal of Thoracic Oncology，2017，12(1)：S1158-S1159.
[17]Shui R，Yu B，Bi R，et al.An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer［J］.Pathology，2016，48(5)：S155-S156.